

Bergen Brunswig Settles Class Action Suit

July 12, 2001

ORANGE, Calif.--July 12, 2001--Bergen Brunswig Corporation (NYSE:BBC), today announced that on July 9, 2001, the Honorable Alicemarie Stotler, United States District Judge for the Central District of California, approved the global settlement of the pending Bergen securities class action, Bergen Capital Trust I class action, and the Huppert derivative action, dismissing with prejudice all pending federal securities class and derivative actions filed against Bergen and certain of its officers and directors arising out of Bergen's acquisition of Stadlander Drug Co., Inc. in January 1999 and its merger with PharMerica, Inc. in April 1999.

Bergen's cash contribution to the settlement was immaterial to its operations, with Bergen's insurers funding the vast majority of the settlement proceeds. The settlement was achieved without any admission of liability by Bergen or its officers and directors. Bergen Brunswig Corporation, headquartered in Orange County, California, is a leading supplier of pharmaceuticals and specialty healthcare products, as well as information management solutions and consulting services. Bergen's customers include the nation's healthcare providers (hospitals, nursing homes and physicians), drug stores, manufacturers and patients. Through its subsidiaries, Bergen provides product distribution; logistics; pharmacy management programs; and Internet fulfillment strategies designed to reduce costs and improve patient outcomes across the entire healthcare spectrum.

Except for historical information, all other information set forth in this press release, such as earnings forecasts and earnings rate projections, consists of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking statements" are subject to risks, uncertainties and other factors which could cause actual results to differ materially from those projected or implied. Such statements may be identified by the use of forward-looking language such as "may," "will," "should," "expect," "anticipate," "estimate," "believe," "think," "continue" or the negatives or other variations thereof or other similar terminology. Such risks and uncertainties include the risks described in exhibit 99(a) to the Company's Annual Report on Form 10-K for the year ended September 30, 2000 and in other reports and exhibits filed with the Securities and Exchange Commission.

These risks and uncertainties include, but are not limited to, the costs and difficulties related to the integration of acquired businesses, the loss or disruption of one or more key customer or supplier relationships, changes in the distribution outsourcing pattern for pharmaceutical products and/or services, the ability to obtain general financing or financing rates that would be compatible with the Company's business operations, and the costs and other effects of governmental regulation and legal and administrative proceedings. The Company assumes no obligation to update the information in the release.